SYRACUSE, NY — October 16, 2025 — Leads & Copy — Repair Biotechnologies, Inc., a biotechnology company focused on developing therapies for atherosclerotic plaque, has announced the appointment of Prof. Frederick J. Raal as a scientific advisor. The company aims to create treatments that can rapidly reduce and stabilize atherosclerotic plaque.
Reason, Chief Executive Officer and Co-Founder of Repair Biotechnologies, expressed enthusiasm for Prof. Raal’s addition to the Scientific Advisory Board, highlighting his expertise in lipid disorders, particularly homozygous familial hypercholesterolemia. Prof. Raal’s clinical expertise will be critical in advancing Repair Biotechnologies’ novel approach to treating patients with severe atherosclerosis and mortality risk.
Prof. Raal noted the difficulty in treating familial hypercholesterolemia and the need for novel therapies to reduce atherosclerosis and prolong the lives of affected patients. He emphasized the importance of safe and reliable methods for regressing and stabilizing atherosclerotic plaque.
Prof. Frederick J. Raal is a Distinguished Professor in the Division of Endocrinology and Metabolism and Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand, Johannesburg, South Africa. He is an NRF A-rated scientist with extensive publications and editorial roles in prominent medical journals. His research focuses on the clinical, biochemical, genetic, and therapeutic management of familial dyslipidemia, particularly heterozygous and homozygous familial hypercholesterolemia.
Contact Information:
Reason.
CEO and Co-Founder
press@repairbiotechnologies.com
+1 315-299-2407
Source: Repair Biotechnologies, Inc.
